Philips’ launch of the VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter in Europe marks a major innovation in minimally invasive cardiology. This first-of-its-kind device features a miniaturized, steerable ultrasound probe—just 3mm in diameter—capable of capturing real-time, high-resolution 2D and 3D images from inside the heart. Unlike traditional transesophageal echocardiography (TEE), VeriSight Pro eliminates the need for general anesthesia and provides unprecedented internal visualization, enabling physicians to assess cardiac anatomy and guide interventions with greater accuracy and speed.
The catheter is designed for structural heart and electrophysiology procedures such as transcatheter valve repair and left atrial appendage closure. By entering through the femoral vein, the device navigates directly into the heart chambers, offering a single access point to conduct a full assessment, guide device placement, and confirm procedural results. This simplified, patient-friendly method reduces the demand for sedation and staff resources, significantly improving hospital workflow and recovery time while maintaining clinical precision.
Now available in Europe, VeriSight Pro is poised to expand access to minimally invasive heart procedures, especially for patients who cannot tolerate traditional imaging methods. Integrated with Philips’ broader structural heart care ecosystem—including its EPIQ ultrasound and Azurion therapy platforms—the system supports a complete, streamlined care pathway. As Philips demonstrates the technology at EuroPCR 2025, it reaffirms its leadership in patient-centric innovation, offering scalable solutions that reduce procedural complexity and elevate outcomes in cardiovascular medicine.
MedTech Spectrum's Summary
Philips' VeriSight Pro is the first 3D intracardiac echocardiography (ICE) catheter to miniaturize real-time 3D imaging technology within a steerable 3mm device, providing high-resolution images from inside the heart without the need for general anesthesia.
The catheter enhances precision and safety during structural heart procedures such as valve repair and left atrial appendage closure by allowing direct, real-time visualization of cardiac anatomy, reducing procedure time and patient risk.
By expanding access to minimally invasive heart procedures across Europe, VeriSight Pro supports better patient outcomes, lowers hospital burden, and exemplifies Philips’ commitment to advancing image-guided cardiovascular care.
